Transcatheter valve implantation for patients with aortic stenosis

Transcatheter aortic valve implantation (TAVI) has expanded the field of treatment of aortic stenosis in high-risk patients. However, the selection of candidates for TAVI and the performance of the procedure require the cooperation of a multidisciplinary team. The current results suggest that TAVI is feasible and provides midterm hemodynamic and clinical improvement in patients with severe symptomatic aortic stenosis at high risk or with contraindications for surgery. Pending questions mainly concern safety and long-term durability. This article describes the main steps for patient selection, the technical aspects of prosthesis implantation, summarizes the current results of TAVI and finally elaborates on future perspectives.

KEYWORDS: aortic stenosis multidisciplinary team patient selection transcatheter aortic valve implantation

Aortic stenosis (AS) is the most frequent valve disease in Europe. It has a predominantly degenerative origin and is therefore mostly present in elderly patients. Valve replacement is the definitive therapy [1]; however, the risk of this treatment may be high in elderly patients with comorbidities. Several registries show that as many as a third of patients with severe valve disease and severe symptoms are not being considered for surgery. Thus, there is a role for less invasive alternatives. Balloon aortic valvuloplasty (BAV) is now rarely used in isolation, mainly due to its limited long-term efficacy [2]. Conversely, transcatheter aortic valve implantation (TAVI) currently represents a dynamic field of research and development 7 years after its introduction in clinical practice by Cribier et al. [3].

This article describes the main steps for patient selection, the technical aspects of prosthesis implantation, summarizes the current results of TAVI and finally elaborates on future perspectives.

Patient selection

As a general principle, the selection of candidates for TAVI and the performance of the procedure requires the cooperation of a multidisciplinary team including cardiologists, surgeons, imaging specialists and anesthesiologists, all with experience in the management of valve disease [4]. Patient selection consists of several steps, which will be described in the following sections.

- Confirmation of the diagnosis
  Transcatheter aortic valve implantation should be performed only in patients with severe symptoms that can definitely be attributed to severe AS as assessed by echocardiography [4]. This relationship could be difficult to establish in elderly patients, especially in the two following situations:
  - In patients with concomitant severe respiratory disease, the medical history, in particular the chronology of dyspnea, as well as dosage of biomarkers such as brain natriuretic peptide, is useful.
  - In patients with low left ventricular (LV) ejection fraction and low gradient, the evaluation of the degree of calcification and low-dose dobutamine echocardiography are useful adjuncts to differentiate between severe and ‘pseudosevere’ AS.

- Evaluation of comorbidities
  Transcatheter aortic valve implantation should not be performed in patients whose life expectancy is very limited in terms of duration and quality of life (<1 year has been proposed as an acceptable threshold).
  Life expectancy is most significantly influenced by comorbidities, which should be carefully looked for. In addition to clinical evaluation, semiquantitative scoring systems, such as those used in geriatrics [5], may be helpful for identifying patients whose life expectancy is compromised more by comorbidities than by heart disease itself. In these latter patients, AS should be managed conservatively.

- Evaluation of the risk of surgery
  Transcatheter aortic valve implantation should currently be restricted to patients at high-risk or with contraindications for surgery. The key
Feasibility of transcatheter aortic valve implantation

When TAVI is envisaged, the following steps should be taken to assess its feasibility:

- Coronary angiography should be performed. If associated coronary artery disease requires revascularization, whether to proceed percutaneously as well as the chronology of intervention should be the subject of individualized discussion based on the patient’s clinical condition and anatomy. In practice, without...
any robust evidence to support it, the trend is to use higher thresholds for combined revascularization than in surgical candidates: revascularization is performed only in cases with severe lesions of the left main coronary trunk, left anterior descending or dominant right coronary artery. In such cases, percutaneous revascularization is usually performed a few weeks before TAVI. Finally, in order to detect coronary implantation that is too low and avoid subsequent coronary obstruction, the position of the coronary arteries relative to the aortic cusps is best assessed using multislice computed tomography (MSCT) (Figure 1).

- Sizing of the valve is critical to minimize the potential for paravalvular leakage and to avoid prosthesis migration after placement or annulus rupture. Several methods are available, but today, the most accurate remains to be determined (Figure 2) [7]. Transthoracic echocardiography is the most popular method, while transesophageal echocardiography (TEE), which has been found to show larger values than transthoracic echocardiography, is advised if borderline values lead to doubt of the feasibility of the procedure. MSCT offers the opportunity to assess the complex 3D structure of the aortic annulus and confirms its oval shape [8]. The measurements obtained by MSCT are somewhat larger than those shown by echocardiography. Finally, measurements of aortography performed during BAV are also advocated by a few teams.

- The morphology of the valve and its length, the importance and location of calcification and the dimensions of the aortic root will also be assessed by echocardiography and MSCT.

- Echocardiography will eliminate the presence of dynamic subvalvular LV obstruction and assess the mitral valve in quantifying the importance of regurgitation and establishing whether mitral disease is organic or functional.

- Evaluation of the peripheral arteries by angiography and, even better, MSCT (Figure 3) will guide the choice of the approach, either retrograde transfemoral or anterograde

| Box 1. Contraindications for transcatheter aortic valve implantation. |
|----------------|-------------------------------------------------|
| **General contraindications** | Aortic annulus of less than 18 mm or greater than 25 mm for balloon-expandable and less than 20 mm or greater than 27 mm for self-expandable devices  
Bicuspid valves (relative contraindication)  
Presence of asymmetric heavy valvular calcification  
Aortic root dimension greater than 45 mm at the sinotubular junction for self-expandable prostheses  
Low position of coronary ostia (<8 mm from the aortic annulus)  
Dynamic subvalvular obstruction  
Severe organic mitral regurgitation  
Apical left ventricular thrombus |
| **Specific contraindications for the transfemoral approach** | Iliac arteries: severe calcification, tortuosity, small diameter (<6–9 mm depending on the device used) or previous aortofemoral bypass  
Aorta: severe angulation, severe atheroma of the arch, coarctation or aneurysm of the abdominal aorta with protruding mural thrombus  
The presence of bulky atherosclerosis of the ascending aorta and arch detected by transesophageal echocardiography. |
| **Contraindications for the transapical approach** | Severe respiratory insufficiency  
Major chest deformity  
Previous surgery of the left ventricular using a patch |
Contraindications for transcatheter aortic valve implantation

The contraindications for TAVI, either general or approach- or device-specific, are shown in Box 1. Some specific issues must be considered:

- Bicuspid aortic valve, especially when severely calcified, is currently a relative contraindication because of the risk of asymmetric deployment of the prosthesis owing to the calcification and the large size of the annulus;
- Asymmetric heavy valvular calcification may compress the coronary arteries during TAVI and should be detected before TAVI on MSCT and also during BAV;

transapical (Figure 4). Size, tortuosity, degree and location of calcification of peripheral arteries will be evaluated in this endeavor.
Dynamic subvalvular obstruction, which may lead to severe hypotension when the valvular obstacle is relieved, should also be looked for carefully, as well as the presence of severe septal hypertrophy localized in the close vicinity of the aortic cusps;

Severe organic mitral regurgitation is a contraindication for TAVI. Conversely, functional MR is not, because it is likely to decrease in the case of a successful procedure.

Techniques of implantation

- General considerations

The performance of TAVI should be restricted to high volume centers that have both cardiology and cardiac surgery departments, with expertise in structural heart disease intervention and high-risk valvular surgery and facilities for cardiac support such as availability of femoral–femoral bypass systems in particular when treating patients with depressed LV ejection fraction [4].

The optimal environment for TAVI should be spacious and sterile and feature high quality imaging equipment and facilities for cardiac support. A hybrid suite is ideal, but in practice very few centers in Europe have the availability of such equipment and most procedures are performed in catheterization laboratories.

Most teams perform the procedure under general anesthesia, although sedation and analgesia may be sufficient for the transfemoral approach. However, it should be kept in mind that the presence of anesthesiologists with specific expertise in cardiology is mandatory for periprocedural care owing to the severe clinical condition of these patients.

The use of general anesthesia allows for peri-procedural TEE monitoring, to help correctly position the valve and even more so to detect complications.

- Devices

Two devices are currently commercialized for TAVI (Figure 5); The Edwards–Sapien™ valve (Edwards Lifesciences, CA, USA), and the Medtronic CoreValve® System (Medtronic, MN, USA). The Edwards–Sapien valve consists of three bovine pericardial leaflets mounted within a tubular, slotted, stainless-steel, balloon-expandable stent. It is currently available in 23 and 26 mm sizes, necessitating, for the transfemoral approach, 22 and 24 Fr, respectively, introducer sheaths for the Retroflex 3™ (Edwards Lifesciences) catheter or 18 and 19 Fr, respectively, introducer sheaths for the Novaflex Catheter™ (Edwards Lifesciences). The transapical approach is performed through a 26 Fr catheter. The Medtronic CoreValve System consists of three porcine pericardial leaflets mounted in a self-expanding nitinol frame. It is available in 26 and 29 mm sizes and goes through 18 Fr introducers for transfemoral or transaxillary use.

Figure 5. Commercially available prostheses. (A) Edwards-Sapien™ transcatheter heart valve and the third generation of RetroFlex™ catheter with the balloon and its distal nose cone. (B) Medtronic CoreValve® System and the third generation 18 Fr catheter.

Figure 6. Possible approaches for transcatheter aortic valve implantation. (A) Transfemoral. The common femoral artery is exposed surgically. The sheath is then passed through the skin to provide a firm anchor. (B) Transapical (Edwards-Sapien). An anterolateral minithoracotomy and a puncture of the left ventricle using a needle through purse-string sutures are performed. (C) Subclavian (Medtronic CoreValve). (D) Transiliac retroperitoneal using an iliac conduit.
Transcatheter aortic valve implantation is currently carried out using two different approaches (Figure 6): retrograde transfemoral or transaxillary and anterograde transapical. The transseptal approach has been abandoned. Specific issues are related to the different approaches.

In the transfemoral approach, the common femoral artery can be either prepared surgically or approached percutaneously. Closure of the vascular access can be effected surgically or using a percutaneous closure device depending on the size of the device and the experience of the team. The same principles hold to be true for the transaxillary approach (Figure 6). Finally, a retroperitoneal approach of the iliac artery (Figure 6) has been used in a few cases.

The transapical approach requires an anterolateral minithoracotomy, pericardiotomy, identification of the apex, then puncture of the left ventricle using a needle through purse-string sutures [9]. Subsequently, an introductory sheath is positioned in the LV and the prosthesis is implanted using the anterograde route.

- **Balloon aortic valvuloplasty**
  After crossing the aortic valve, BAV is performed to predilate the native valve just before prosthesis implantation. Similar to the procedure performed when using surgical valve replacement, BAV could be used as a bridge to TAVI in patients presenting with very low LV ejection fraction or in acute heart failure. This stepwise approach performed at an interval of a few days or weeks may decrease the risk of intervention.

- **Prosthesis positioning**
  Positioning the prosthesis at the level of the aortic valve is a crucial step and may use fluoroscopy and echocardiography in combination:
  - Fluoroscopy is useful to assess the level of valve calcification and aortography to determine the position of the valve and the plane of alignment of the aortic cusps.
  - Transesophageal echocardiography is helpful, in particular, in cases with moderate calcification. The additional value of 3D real-time TEE is currently being evaluated. According to the limited current experience with intracardiac echography, it does not appear to enhance TEE in this setting.

- **Prosthesis implantation**
  When positioning is considered correct, the prosthesis is released. Rapid pacing is used at this stage in balloon-expandable valves but not in self-expanding devices to decrease cardiac output and stabilize the prosthesis during inflation (Figure 7).
Immediately after TAVI, aortography and, whenever available, TEE are performed to assess the location and degree of aortic regurgitation (AR), the patency of the coronary arteries and also to rule out complications such as hemopericardium and aortic dissection (Figure 8). The hemodynamic results are assessed using pressure recordings and/or echocardiography.

Postprocedural care
After the procedure, the patients should stay in intensive care for at least 24 h and hemodynamics, vascular access and rhythm disturbances, especially late atrioventricular blockage, should be closely monitored for several days.

On an empirical basis, dual antiplatelet therapy is usually administered for 3–6 months and aspirin is continued for the rest of the patients life. If vitamin K blockers are required, the duration of dual antiplatelet treatment should be made shorter or a single agent should be considered.

Results
General considerations
More than 10,000 cases of TAVI have been performed worldwide; however, it should be noted that the evidence in this field remains limited. A number of single center reports were published in peer-reviewed journals but they seldom included more than 100 cases and were a mix of early and late experience as well as first and subsequent generation devices [10–12]. The second source of information is registries [13–16], mostly reported in oral presentations with all the inherent limitations. In addition, the series are heterogeneous with regard to the approach or device used. In most reports, the transfemoral approach is the default approach and, therefore, the patients treated using the transapical approach usually have a higher-risk profile and more comorbidities, which should be kept in mind when analyzing the results. There are currently no studies comparing either one device against the other or one approach against the other. The overall results are shown in Tables 1–3.

Table 1. Baseline characteristics of patients treated by transcatheter aortic valve implantation.

<table>
<thead>
<tr>
<th></th>
<th>Edwards-Sapien</th>
<th>Edwards-Sapien</th>
<th>Edwards-Sapien + CoreValve</th>
<th>CoreValve</th>
<th>CoreValve</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Webb† (n = 168)</td>
<td>SOURCE‡ (n = 1038)</td>
<td>Bichat§ (n = 120)</td>
<td>Post-CE registry # (n = 1483)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>84</td>
<td>81 ± 7</td>
<td>81 ± 9</td>
<td>81 ± 7</td>
<td>81 ± 6</td>
</tr>
<tr>
<td>Female sex</td>
<td>81 (48.2)</td>
<td>575 (55)</td>
<td>54 (45)</td>
<td>348 (54)</td>
<td>816 (55)</td>
</tr>
<tr>
<td>NYHA class III/IV</td>
<td>145 (86.3)</td>
<td>–</td>
<td>116 (97)</td>
<td>532 (85)</td>
<td>1246 (84)</td>
</tr>
<tr>
<td>Coronary artery disease:</td>
<td>–</td>
<td>539 (52)</td>
<td>71 (59)</td>
<td>367 (57)</td>
<td>890 (60)</td>
</tr>
<tr>
<td>– Previous MI</td>
<td>123 (73.2)</td>
<td>–</td>
<td>24 (20)</td>
<td>77 (12)</td>
<td>–</td>
</tr>
<tr>
<td>– Previous PCI</td>
<td>–</td>
<td>–</td>
<td>26 (22)</td>
<td>187 (30)</td>
<td>415 (28)</td>
</tr>
<tr>
<td>– Previous CABG</td>
<td>62 (36.9)</td>
<td>235 (23)</td>
<td>34 (28)</td>
<td>130 (20)</td>
<td>311 (21)</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>60 (35.7)</td>
<td>208 (20)</td>
<td>18 (15)</td>
<td>144 (23)</td>
<td>356 (24)</td>
</tr>
<tr>
<td>Renal failure</td>
<td>20 (11.9)</td>
<td>310 (30)</td>
<td>42 (35)</td>
<td>–</td>
<td>400 (27)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>39 (23)</td>
<td>–</td>
<td>26 (22)</td>
<td>172 (27)</td>
<td>386 (26)</td>
</tr>
<tr>
<td>Severe COPD</td>
<td>35 (20.8)</td>
<td>286 (28)</td>
<td>32 (27)</td>
<td>–</td>
<td>371 (25)</td>
</tr>
<tr>
<td>Previous cerebrovascular event</td>
<td>30 (17.9)</td>
<td>–</td>
<td>–</td>
<td>48 (8)</td>
<td>133 (9)</td>
</tr>
<tr>
<td>Porcelain aorta</td>
<td>36 (21.4)</td>
<td>87 (8)</td>
<td>14 (12)</td>
<td>33 (7)</td>
<td>119 (8)</td>
</tr>
<tr>
<td>Aortic valve area (cm²)</td>
<td>0.6 (0.5–0.7)</td>
<td>–</td>
<td>0.7 ± 0.2</td>
<td>0.6 ± 0.2</td>
<td>0.6 ± 0.2</td>
</tr>
<tr>
<td>Mean gradient (mmHg, mean ± SD)</td>
<td>46 (34–55)</td>
<td>–</td>
<td>52 ± 15</td>
<td>49 ± 14</td>
<td>49 ± 6</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>–</td>
<td>–</td>
<td>51 ± 15</td>
<td>51 ± 14</td>
<td>52 ± 14</td>
</tr>
<tr>
<td>Logistic EuroSCORE (%)</td>
<td>29 (22–27)</td>
<td>27 ± 15</td>
<td>27 ± 14</td>
<td>23 ± 14</td>
<td>23 ± 14</td>
</tr>
<tr>
<td>STS-PROM (%)</td>
<td>9 (6–13)</td>
<td>–</td>
<td>16 ± 9</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Pulmonary hypertension &gt;60 mmHg</td>
<td>45 (26.8)</td>
<td>–</td>
<td>29 (24)</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

†Data taken from [10]. ‡Data taken from EuroPCR 2009. §Data taken from European Society Cardiology Barcelona 2009. †Data taken from [16]. #Data taken from EuroPCR 2009. Values are expressed as n (%), mean ± SD or median (Q1–Q3).
CABG: Coronary artery bypass grafting; COPD: Chronic obstructive pulmonary disease; LVEF: Left ventricular ejection fraction; MI: Myocardial infarction; NYHA: New York Heart Association; PCI: Percutaneous coronary intervention; SD: Standard deviation; STS-PROM: Society of Thoracic Surgeons Predicted Risk of Mortality.
Screening

The reports considering the management of severe AS in the era of TAVI by recent observation demonstrated that approximately 60% of the patients screened by a multidisciplinary team for the procedure are currently treated by TAVI if both approaches are available, while 10–20% of patients are operated on, and finally, approximately 30% of patients are treated medically. These respective percentages would vary according to whether only one device or both devices were used and the availability of all the approaches versus the availability of transfemoral approach alone. Overall, the availability of TAVI has increased the number of referrals for intervention in patients with severe AS, which is a good thing, taking into consideration the current underuse of surgery in this population [17].

Procedure

The two types of devices are used more or less equally. Overall, two out of three of cases have been performed using the transfemoral approach and only preliminary reports describe the experience of the transaxillary route in approximately 200 patients.

The most recent registries report procedural success rates exceeding 90% in experienced centers [10-13,16]. However, it is important to acknowledge that all reports consistently show a learning curve effect, both on the success

Table 2. The 30-day outcomes in patients treated by transfemoral aortic valve implantation.

<table>
<thead>
<tr>
<th></th>
<th>Webb† (n = 113)</th>
<th>SOURCE‡ (n = 463)</th>
<th>Bichat§ (n = 83)</th>
<th>Piazza‡ (n = 646)</th>
<th>Post-CE registry⁴ (n = 1483)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implantation success</td>
<td>–</td>
<td>95.2</td>
<td>94</td>
<td>97.2</td>
<td>98.5</td>
</tr>
<tr>
<td>Aortic valve area (cm²)</td>
<td>–</td>
<td>–</td>
<td>1.7</td>
<td>–</td>
<td>1.5</td>
</tr>
<tr>
<td>Mean gradient (mmHg)</td>
<td>–</td>
<td>–</td>
<td>11</td>
<td>3</td>
<td>9</td>
</tr>
<tr>
<td>Paravalvular aortic regurgitation &gt; grade 2</td>
<td>–</td>
<td>1.5</td>
<td>3</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td>Valve-in-valve implantation</td>
<td>–</td>
<td>0.6</td>
<td>2</td>
<td>2.6</td>
<td>–</td>
</tr>
<tr>
<td>Major vascular complications</td>
<td>8.0</td>
<td>10.6</td>
<td>12</td>
<td>1.9</td>
<td>3.8</td>
</tr>
<tr>
<td>Stroke</td>
<td>5.3</td>
<td>2.4</td>
<td>5</td>
<td>0.6</td>
<td>2.2</td>
</tr>
<tr>
<td>Tamponade</td>
<td>1.8</td>
<td>–</td>
<td>2</td>
<td>1.4</td>
<td>3.6</td>
</tr>
<tr>
<td>Valve embolization</td>
<td>–</td>
<td>0</td>
<td>0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Coronary obstruction</td>
<td>–</td>
<td>0.7</td>
<td>1.2</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td>Renal failure requiring dialysis</td>
<td>1.8</td>
<td>1.3</td>
<td>0</td>
<td>–</td>
<td>2.2</td>
</tr>
<tr>
<td>Need for new pacemaker</td>
<td>5.4</td>
<td>6.7</td>
<td>12</td>
<td>9.3</td>
<td>25</td>
</tr>
<tr>
<td>Conversion to open heart surgery</td>
<td>0</td>
<td>–</td>
<td>0</td>
<td>0.5</td>
<td>0.8</td>
</tr>
<tr>
<td>Mortality at 30 days</td>
<td>8</td>
<td>6.3</td>
<td>8</td>
<td>8</td>
<td>10.3</td>
</tr>
</tbody>
</table>

Values are expressed as % unless otherwise stated.
†Data taken from [10]. ‡Data taken from EuroPCR 2009. §Data taken from European Society of Cardiology Barcelona 2009. ¶Data taken from [16]. †Data taken from EuroPCR 2009.

Table 3. Transapical aortic valve implantation (Edwards-Sapien) 30-day results.

<table>
<thead>
<tr>
<th></th>
<th>Webb† (n = 55)</th>
<th>SOURCE‡ (n = 575)</th>
<th>Bichat§ (n = 37)</th>
<th>France‡ (n = 71)</th>
<th>PARTNER EU³ (n = 69)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implant success (%)</td>
<td>–</td>
<td>93</td>
<td>100</td>
<td>97</td>
<td>91</td>
</tr>
<tr>
<td>Death (%)</td>
<td>18</td>
<td>10</td>
<td>11</td>
<td>17</td>
<td>19</td>
</tr>
<tr>
<td>Stroke (%)</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Coronary obstruction</td>
<td>–</td>
<td>1</td>
<td>0</td>
<td>–</td>
<td>3</td>
</tr>
<tr>
<td>Permanent pacemaker (%)</td>
<td>7</td>
<td>7</td>
<td>3</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Vascular complications (%)</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>Aortic regurgitation &gt;2/4 (%)</td>
<td>–</td>
<td>2</td>
<td>8</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Conversion to AVR (%)</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Tamponade (%)</td>
<td>4</td>
<td>–</td>
<td>11</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

rate and the incidence and severity of complications, which emphasizes the importance of careful training.

Early results & complications
Valve function after the procedure is good, with a final valve area ranging from 1.5 to 1.8 cm² and mean gradients of approximately 10 mmHg or less, which is at least equivalent to that of surgically implanted prostheses [18]. Recent observations using MSCT demonstrated that in up to 20% of cases the shape of the prosthesis may be elliptical after implantation, which may favor paravalvular AR (Figure 9).

Coronary obstruction is a rare (<1%) but dramatic complication [19]. It may be due to external compression of the left main coronary artery by bulky valve calcification or obstructive low-positioned coronary ostia. Acute myocardial infarction occurs in 2–5% of cases. Mild AR, mostly paravalvular, is observed in over 50% of cases. Moderate AR occurs in approximately 20% of cases. The availability of larger prostheses and their more careful matching with the size of the aortic annulus in order to slightly enlarge the size of the device has led to a decrease in the incidence of severe AR to less than 10% [20]. Prosthesis embolization is rare, occurring in approximately 1% of cases [21]. Stroke rate ranges from 2 to 9%, with a trend towards a lower incidence of strokes when using the transapical approach [10–14]. Finally, recent reports emphasize the risk of impairment of kidney function in this highly vulnerable population [22].

Vascular complications remain a significant cause of morbidity in the transfemoral approach with an incidence ranging from 10 to 15% with the balloon-expandable device, decreasing to 2–4% with the self-expandable type that has a lower profile (Figure 10) [23].

Atrioventricular block occurs in 4–8% with the balloon-expandable devices, necessitating pacemaker implantation in up to 30% of cases with self-expandable devices [24]. The presence of previous right bundle branch block and the onset of left bundle branch block during the procedure are predictors of the need for pacemaking after TAVI [25].

The transapical approach, which requires a thoracotomy and ventriculotomy, may lead to specific postoperative complications as well as rare LV apical aneurysms.

Surgical conversion is rare but requires the immediate availability of cardiac support and surgical back up, at least in operable patients,
Overall, mortality at 30 days ranges from 5 to 18% for the transfemoral approach and from 10 to 19% when using the transapical approach [10–14,16].

Finally, case reports have shown the feasibility of ‘valve-in-valve implantation’ (Figure 11) for either acute failure of TAVI caused by intra-prosthetic AR or for either stented or stentless degenerated valve prostheses [26]; however, it is too early to draw any definite conclusions on this attractive potential indication.

Late results
The majority of late adverse clinical events are due to comorbidities. Anecdotal cases of valve endocarditis or thromboembolism have been reported. The risk of bleeding could be a concern in elderly patients when receiving a combination of antiplatelet agents plus vitamin K blockers. The degree of AR remains stable over time and mild-to-moderate AR did not require reintervention or cause severe hemolysis during this limited follow-up. Serial echocardiographic studies have consistently shown good prosthetic valve function and no structural deterioration of valve tissue has been reported so far. A few cases of secondary surgical intervention have been performed, mostly in cases of inadequate valve positioning. Preliminary reports have shown that LV ejection fraction improves after TAVI while the degree of functional MR decreases [10].

Long-term results up to 6 years (although only 1 year to a maximum of 3 years in most studies) demonstrate a survival rate of 70% at 1 year and 60% at 2 years with a significant improvement in clinical condition and quality of life parameters in most cases, which is of utmost importance in the elderly population [27].

Upcoming data
It is necessary to accumulate more evidence on the results of TAVI. The results of the first randomized trial (PARTNER US), comparing TAVI with either medical therapy or surgical valve replacement according to patients’ condition, will be reported during the coming year. Data should be accumulated from registries with longer follow-up to assess safety and durability with special focus on the timing and the mode of valve failure, the consequences of mild-to-moderate AR and the feasibility of either percutaneous or surgical reintervention. These data will help to better define the indications of the technique and the respective place of each approach.

Conclusion
The current results suggest that TAVI is feasible and provides hemodynamic and clinical improvement for up to 3 years in patients with severe symptomatic AS at high-risk or with contraindications for surgery. Pending questions mainly concern safety and long-term durability. Surgeons and cardiologists must work as a team to select the best candidates, perform the procedure and, finally, evaluate the results. At present, these techniques are targeted at high-risk patients.

Future perspective
Progress in delivery systems and valve manufacturing will lead to overcoming what are currently the main limitations of TAVI; lower profile enabling a decrease of the sheath size for the transfemoral approach and a wider range of...
prosthetic valve dimensions to better adapt to the annulus size. The new generation devices are also expected to be repositionable, retrievable, more durable and to ensure a better ceiling. Further improvements in imaging will also play an important role in refining valve sizing in order to reduce the incidence of AR. Computerized systems derived from conventional angiography will allow 3D reconstruction of the aortic root anatomy to facilitate valve placement. More generally, a continued search should be made to improve procedural strategies, especially safety, in order to minimize the impact on the myocardium, brain and kidneys. In particular, the search should be continued to reduce the incidence of periprocedural stroke.

The respective role of TAVI and surgical valve replacement is likely to change in the future with an anticipated increase in the use of TAVI, which will hopefully be based on evidence more than on uncontrolled off-label use of the devices. Furthermore, it is also likely that the availability of TAVI will lead to a lowering of the age of implantation of surgical bioprosthesis with the expectation of performing a secondary ‘valve-in-valve’ procedure. At this stage, it is important to keep in mind that TAVI is not recommended for patients who simply refuse surgery on the basis of personal preference owing to the awareness of TAVI. However, the indications of TAVI may well be extended to lower risk groups in the future if the initial promise holds true after careful evaluation.

Financial & competing interests disclosure
Dominique Himbert is proctor for Edwards Lifesciences. Alec Vahanian is consultant for Edwards Lifesciences. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Executive summary

Patient selection
- Patient selection consists of confirmation of the diagnosis, evaluation of comorbidities and evaluation of the risk of surgery.

Transcatheter aortic valve implantation feasibility
- The evaluation of transcatheter aortic valve implantation (TAVI) feasibility includes the following steps:
  - Coronary issues: a coronary angiogram is made to search for associated coronary artery disease. Low coronary implantation is best assessed using multislice computed tomography (MSCT);
  - Sizing of the valve (trans thoracic echocardiography, transesophageal echocardiography and MSCT);
  - Evaluation of the morphology of the valve and its length, calcifications and dimensions of the aortic root (trans thoracic echocardiography, transesophageal echocardiography and MSCT);
  - Evaluation of the peripheral arteries (angiography and MSCT).

Prosthesis implantation
- Two devices are currently commercialized for TAVI: the Edwards-Sapien™ valve and the Medtronic CoreValve® System.
- Transcatheter aortic valve implantation is currently carried out using two different approaches: retrograde transfemoral or transaxillary and anterograde transapical.

Results & complications
- With careful screening and experience, the current techniques achieve a high immediate success rate.
- Valve function after TAVI is good in terms of hemodynamics. Mild aortic regurgitation (AR) is frequent; however, severe AR is rare.
- After a follow-up up to 3 years, hemodynamic and functional results are satisfactory, especially taking into account the patient’s risk profile.

Future perspective
- Progress in delivery systems and valve manufacturing are expected.
- Pending questions remain on safety and long-term durability of the valve prosthesis.
- The respective role of TAVI and surgical valve replacement is likely to change in the future with an anticipated increase in the use of TAVI if the initial promise holds true after careful evaluation.

Bibliography

Papers of special note have been highlighted as:
* of interest
** of considerable interest

** Document issued by both medical and surgical scientific societies to set the stage for the use of transcatheter aortic valve implantation.


** Comparative evaluation of the predictive value of the risk scores for aortic valve replacement.


* Comparative evaluation of transcranial echocardiography, transesophageal echocardiography and multislice computed tomography performances for aortic annulus diameter evaluation.


** Pioneering work on the role of multislice computed tomography during transcatheter aortic valve implantation.


** Largest single center series using the balloon-expandable prosthesis.


* Largest single center study using the self-expandable device.


* Largest report on the transapical approach.


* Largest North American registry on the transapical approach.


